Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study

被引：30

作者：

De Vita, Ferdinando ^{[1
]}

Borg, Christophe ^{[2
]}

Farina, Gabriella ^{[3
]}

Geva, Ravit ^{[4
]}

Carton, Iris ^{[5
]}

Cuku, Hera ^{[6
]}

Wei, Ran ^{[7
]}

Muro, Kei ^{[8
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, Div Med Oncol, I-80138 Naples, Italy

[2] Univ Hosp Besancon, Dept Med Oncol, F-25000 Besancon, France

[3] Fatebenefratelli Sacco Hosp, Dept Med Oncol, I-20121 Milan, Italy

[4] Tel Aviv Univ, Oncol Div, IL-6997801 Tel Aviv, Israel

[5] Eli Lilly & Co, B-1000 Brussels, Belgium

[6] Eli Lilly & Co, I-50019 Florence, Italy

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 4648681, Japan

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 23期

关键词：

gastric cancer; HER-2; inhibitor; prior trastuzumab; ramucirumab plus paclitaxel; targeted therapy; VEGFR-2; ENDOTHELIAL GROWTH-FACTOR; ADENOCARCINOMA; CHEMOTHERAPY; MULTICENTER;

D O I：

10.2217/fon-2019-0243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: This subgroup analysis of the RAINBOW study evaluated the efficacy and safety of ramucirumab in patients with gastric cancer/gastroesophageal junction adenocarcinoma who received prior trastuzumab therapy. Patients & methods: Of adult patients enrolled in the RAINBOW study, 39 had received prior trastuzumab therapy. Of these, 20 patients were treated with ramucirumab plus paclitaxel and 19 patients with placebo plus paclitaxel within the RAINBOW trial. Results: Overall survival was longer with ramucirumab plus paclitaxel (11.4 months; 95% CI: 7.0-17.9) versus placebo plus paclitaxel (7.0 months; 95% CI: 3.4-14.6), hazard ratio: 0.68 (0.33-1.41); p = 0.30. Longer progression-free survival, higher objective response were observed in ramucirumab combination group. Conclusion: Ramucirumab plus paclitaxel demonstrated efficacy benefits with manageable safety profile in a subgroup of patients pretreated with trastuzumab.

引用

页码：2723 / 2731

页数：9

共 50 条

[1] Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study (vol 15, pg 2723, 2019)
De Vita, Ferdinando
Borg, Christophe
Farina, Gabriella
Geva, Ravit
Carton, Iris
Cuku, Hera
Wei, Ran
Muro, Kei
[J]. FUTURE ONCOLOGY, 2021, 17 (25)
[2] Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer
Muro, Kei
Oh, Sang Cheul
Shimada, Yasuhiro
Lee, Keun-Wook
Yen, Chia-Jui
Chao, Yee
Cho, Jae Yong
Cheng, Rebecca
Carlesi, Roberto
Chandrawansa, Kumari
Orlando, Mauro
Ohtsu, Atsushi
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (03) : 581 - 589
[3] A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients
Imazeki, Hiroshi
Sakamoto, Takeshi
Nakano, Michitaka
Negoro, Yuji
Yamaga, Satoru
Kawakami, Kentaro
Nishikawa, Kazuo
Izawa, Naoki
Boku, Narikazu
Tsuda, Masahiro
Esaki, Taito
Makiyama, Akitaka
Okuda, Hiroyuki
Tsuda, Takashi
Minashi, Keiko
Hironaka, Shuichi
[J]. ANNALS OF ONCOLOGY, 2019, 30
[4] Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW
Muro, Kei
Cho, Jae Yong
Bodoky, Gyorgy
Goswami, Chanchal
Chao, Yee
dos Santos, Lucas V.
Shimada, Yasuhiro
Topuzov, Eldar
Van Cutsem, Eric
Tabernero, Josep
Zalcberg, John
Chau, Ian
Cascinu, Stefano
Cheng, Rebecca
Hsu, Yanzhi
Emig, Michael
Orlando, Mauro
Fuchs, Charles
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (04) : 814 - 824
[5] Ramucirumab plus paclitaxel for gastric cancer in China
Yoon, Harry H.
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (12): : 975 - 976
[6] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
Akira Sawaki
Yasuo Ohashi
Yasushi Omuro
Taroh Satoh
Yasuo Hamamoto
Narikazu Boku
Yoshinori Miyata
Hiroya Takiuchi
Kensei Yamaguchi
Yasutsuna Sasaki
Tomohiro Nishina
Atsushi Satoh
Eishi Baba
Takao Tamura
Takashi Abe
Kiyohiko Hatake
Atsushi Ohtsu
[J]. Gastric Cancer, 2012, 15 : 313 - 322
[7] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
Sawaki, Akira
Ohashi, Yasuo
Omuro, Yasushi
Satoh, Taroh
Hamamoto, Yasuo
Boku, Narikazu
Miyata, Yoshinori
Takiuchi, Hiroya
Yamaguchi, Kensei
Sasaki, Yasutsuna
Nishina, Tomohiro
Satoh, Atsushi
Baba, Eishi
Tamura, Takao
Abe, Takashi
Hatake, Kiyohiko
Ohtsu, Atsushi
[J]. GASTRIC CANCER, 2012, 15 (03) : 313 - 322
[8] Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer
Roviello, Giandomenico
Conca, Raffaele
D'Angelo, Alberto
Multari, Andrea Giovanni
Paganini, Giovanni
Chiriaco, Giorgio
Petrioli, Roberto
Corona, Silvia Paola
Rosellini, Pietro
Aieta, Michele
[J]. ANTI-CANCER DRUGS, 2020, 31 (06) : 632 - 636
[9] Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel
Roviello, Giandomenico
Corona, Silvia P.
Multari, Andrea G.
Petrioli, Roberto
Rosellini, Pietro
Aieta, Michele
[J]. ANTI-CANCER DRUGS, 2019, 30 (07) : 745 - 748
[10] Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer.
Fukuda, Naoki
Takahari, Daisuke
Osumi, Hiroki
Matsushima, Tomohiro
Nakayama, Izuma
Wakatsuki, Takeru
Ogura, Mariko
Ichimura, Takashi
Ozaka, Masato
Suenaga, Mitsukuni
Shinozaki, Eiji
Chin, Keisho
Yamaguchi, Kensei
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 2 3 4 5 →